Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation
Thiogenesis Therapeutics' (TTI.V)on Monday said its lead drug candidate, TTI-0102, for the treatment of Leigh syndrome has been granted Rare Pediatric Disease designation by the US Food and Drug Administration (FDA). The designation provides the company with the potential to receive a priority review voucher, after approval of a future new drug application, said the company. "Receiving Rare Pediatric Disease designation is an important regulatory milestone for our Leigh syndrome spectrum program and further expands Thiogenesis' regulatory portfolio," said Chief Executive Officer Patrice Rioux. The company's shares last traded July 10, closing at C$0.56 on the TSX Venture Exchange.
Thiogenesis Therapeutics' (TTI.V)on Monday said its lead drug candidate, TTI-0102, for the treatment of Leigh syndrome has been granted Rare Pediatric Disease designation by the US Food and Drug Administration (FDA).
The designation provides the company with the potential to receive a priority review voucher, after approval of a future new drug application, said the company. "Receiving Rare Pediatric Disease designation is an important regulatory milestone for our Leigh syndrome spectrum program and further expands Thiogenesis' regulatory portfolio," said Chief Executive Officer Patrice Rioux.
The company's shares last traded July 10, closing at C$0.56 on the TSX Venture Exchange.